COVID-19

Small antibodies called nanobodies produced in camels, llamas, and alpacas might help stop the spread of COVID-19, but can they stand up against the competition?

Before its COVID-19 era hype, ivermectin was already a wonder drug for parasitic infections. Its renewed interest underscores the need for effective COVID-19 treatments and communication on proper research study design and analysis.

LIVE November 29th, 2021 at 11:00 AM ET
Investigating the pathophysiology and spread of human viruses

A new delivery system initially developed to treat asthma sends corticosteroids deep into the lungs where COVID-19 infects cells, potentially slowing viral replication.

LIVE October 26th, 2021 at 11:00 AM ET
Experts will discuss recent advances in screening strategies to more efficiently identify therapeutic candidates for infectious diseases such as schistosomiasis and COVID-19.

Respiratory viruses are the most common cause of asthma attacks, but COVID-19 does not send asthma patients to the hospital more often than others. Some researchers suspect that having asthma may actually protect patients from severe COVID-19.

Experiments in ferrets show that a prophylactic spray cuts SARS-CoV-2 replication by more than 90 percent by priming the innate immune system.

Researchers are conducting the first long-term prospective study to understand the immune response to COVID-19 long after initial infection.

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.

Researchers combined genome, phenotype, and proteome-wide association assays to identify protein variants associated with severe COVID-19, providing clues for how these proteins may contribute to disease.